Abstract
Rationale & Objectives
A strategic assessment of the competitive environment is unquestionably one of
the highest priority management responsibilities crucial to business survival,
growth and profitability. Timely and factual competitive intelligence is vital
to the success of all business functions, especially Planning, Marketing, R&D
and Manufacturing. In a highly dynamic and fragmented pharmaceutical market,
besieged by intense competition,the rapid pace of technological innovations,
and the uncertainty regarding future government regulations, the ability to
anticipate new competitive product introductions and marketing strategies is
particularly important... and spells the difference between success and
failure.
The Top 10, a unique series of market intelligence studies introduced
VENTURE PLANNING GROUP in 1987, is designed to provide the pharmaceutical
industry executives with strategically significant competitor information,
analysis, and insight critical to the development and implementation of
effective marketing and R&D programs.
The study' s major objectives include:
- To establish a comprehensive, factual, annually-updated and costeffective
information base on performance, capabilities, goals and strategies of the
world' s leading pharmaceutical companies.
- To help current suppliers realistically assess their financial, marketing
and technological capabilities vis-a-vis leading competitors.
- To assist potential market entrants in evaluating prospective acquisitions
and joint venture candidates.
- To complement organizations' internal competitor information gathering
efforts by providing strategic analysis, data interpretation and insight.
- To identify the least competitive market niches with significant growth
potential.
Methodology
VENTURE PLANNING GROUP' S DATABASE
VPG' s proprietary data files contain current information on major
pharmaceutical companies, technologies, products and executives worldwide.
These files, developed in the course of over 100 syndicated and numerous
single-client studies, were thoroughly searched to retrieve any information
pertinent to the Top 10 companies' capabilities and strategies.
SECONDARY INFORMATION SOURCES
A comprehensive review of the Top 10 companies' product and financial
literature, business and technical periodicals, and pertinent industry analyst
reports was conducted.
Table of Contents
WORLDWIDE MARKET DYNAMICS AND TRENDS
COMPANY STRATEGIC ASSESSMENTS
SECTION I: EXECUTIVE SUMMARY
- A 5-10 page synopsis of key sections.
SECTION II: BUSINESS ORGANIZATION
- History of the company' s pharmaceutical business evolution, which is
important to understanding the corporate culture, management mentality, and
strategies.
- Most recent M&A activity and significant organizational changes.
- Current organizational structure.
SECTION III: SENIOR MANAGEMENT
- Names, titles, and background of senior managers.
SECTION IV: FACILITIES AND EMPLOYEES
- Major administrative, manufacturing, and R&D facilities in the U.S. and
abroad.
- Manufacturing practices.
- New plants under construction.
- U.S. and international work force size and distribution.
SECTION V:TECHNOLOGICAL KNOW-HOW
- Internally developed and acquired technologies, processes, and related
capabilities.
- Know-how in biotechnology and other pertinent fields.
- Proprietary technologies and patent litigations.
SECTION VI: PRODUCT PORTFOLIO ANALYSIS
- Extensive review of major ethical, OTC, and generic drugs.
- Most recent new drug introductions and indications.
SECTION VII: MARKETING TACTICS
- Sales force size and structure in the U.S., Europe, Japan, and other
regions.
- Major sales office locations.
SECTION VII: MARKETING TACTICS
- Sales force in the U.S., Europe, and other regions.
- Distribution strategies.
- Major promotional tactics.
SECTION VIII: FINANCIAL ANALYSIS
- The U.S. and international sales and operating profit estimates by
division, geographic region, therapeutic category, and individual drug.
- The five-year sales and operating profit performance.
SECTION IX: R&D EXPENDITURES AND MAJOR PROGRAMS
- The R&D budget.
- Research facilities and staff.
- New technologies, drugs, and indications in development, including their
phase and anticipated introduction dates.
SECTION X: COLLABORATIVE ARRANGEMENTS
- Major joint venture, distribution, OEM, and licensing partners, both
industrial and academic.
- Terms of collaborative agreements and specific products involved.
SECTION XI: STRATEGIC DIRECTION
- Major strengths and weaknesses.
- Business, new product development, and marketing objectives and strategies.
- Anticipated acquisitions, joint ventures, and divestitures.
- Worldwide sales force size.
COMPARATIVE ANALYSIS
In this section of the report, the Top 10 companies are ranked according to
the following criteria:
- Worldwide sales and rank products.
- Operating profit and margins.
- R&D expenditures.
|
